PURPOSE: Trachoma is to be eliminated as a public health problem by 2020. To help the process of planning interventions where needed, and to provide a baseline for later comparison, we set out to complete the map of trachoma in Afar, Ethiopia, by estimating trachoma prevalence in evaluation units (EUs) of grouped districts ("woredas"). METHODS: We conducted seven community-based surveys from August to October 2013, using standardised Global Trachoma Mapping Project (GTMP) survey methodologies. RESULTS: We enumerated 5065 households and 18,177 individuals in seven EUs covering 19 of Afar's 29 woredas; the other ten were not accessible. 16,905 individuals (93.0%) were examined, of whom 9410 (55.7%) were female. One EU incorporating four woredas (Telalak, Dalefage, Dewe, Hadele Ele) was shown to require full implementation of the SAFE strategy for three years before impact survey, with a trachomatous inflammation-follicular (TF) prevalence in 1-9-year-olds of 17.1% (95%CI 9.4-25.5), and a trichiasis prevalence in adults aged ≥15 years of 1.2% (95%CI 0.6-2.0). Five EUs, covering 13 woredas (Berahle, Aba'ala, Dupti, Kurri, Elidihare, Ayesayeta, Afamboo, Bure Mudaitu, Gewane, Amibara, Dulecho, Dalolo, and Konebo), had TF prevalences in children of 5-9.9% and need one round of azithromycin mass treatment and implementation of the F and E components of SAFE before re-survey; three of these EUs had trichiasis prevalences in adults ≥0.2%. The final EU (Mile, Ada'ar) had a sub-threshold TF prevalence and a trichiasis prevalence in adults just >0.2%. CONCLUSION: Trachoma is a public health problem in Afar, and implementation of the SAFE strategy is required.
PURPOSE: Trachoma is to be eliminated as a public health problem by 2020. To help the process of planning interventions where needed, and to provide a baseline for later comparison, we set out to complete the map of trachoma in Afar, Ethiopia, by estimating trachoma prevalence in evaluation units (EUs) of grouped districts ("woredas"). METHODS: We conducted seven community-based surveys from August to October 2013, using standardised Global Trachoma Mapping Project (GTMP) survey methodologies. RESULTS: We enumerated 5065 households and 18,177 individuals in seven EUs covering 19 of Afar's 29 woredas; the other ten were not accessible. 16,905 individuals (93.0%) were examined, of whom 9410 (55.7%) were female. One EU incorporating four woredas (Telalak, Dalefage, Dewe, Hadele Ele) was shown to require full implementation of the SAFE strategy for three years before impact survey, with a trachomatous inflammation-follicular (TF) prevalence in 1-9-year-olds of 17.1% (95%CI 9.4-25.5), and a trichiasis prevalence in adults aged ≥15 years of 1.2% (95%CI 0.6-2.0). Five EUs, covering 13 woredas (Berahle, Aba'ala, Dupti, Kurri, Elidihare, Ayesayeta, Afamboo, Bure Mudaitu, Gewane, Amibara, Dulecho, Dalolo, and Konebo), had TF prevalences in children of 5-9.9% and need one round of azithromycin mass treatment and implementation of the F and E components of SAFE before re-survey; three of these EUs had trichiasis prevalences in adults ≥0.2%. The final EU (Mile, Ada'ar) had a sub-threshold TF prevalence and a trichiasis prevalence in adults just >0.2%. CONCLUSION: Trachoma is a public health problem in Afar, and implementation of the SAFE strategy is required.
Authors: Paul M Emerson; Steve W Lindsay; Neal Alexander; Momodou Bah; Sheik-Mafuji Dibba; Hannah B Faal; Kebba O Lowe; Keith P W J McAdam; Amy A Ratcliffe; Gijs E L Walraven; Robin L Bailey Journal: Lancet Date: 2004-04-03 Impact factor: 79.321
Authors: Sadik Taju Sherief; Colin Macleod; Goitum Gigar; Hagos Godefay; Atakelit Abraha; Michael Dejene; Amir B Kello; Aberash Belete; Yitbarek Assefa; Rebecca Willis; Brian K Chu; Anthony W Solomon Journal: Ophthalmic Epidemiol Date: 2016-12-05 Impact factor: 1.648
Authors: Anthony W Solomon; Alexandre L Pavluck; Paul Courtright; Agatha Aboe; Liknaw Adamu; Wondu Alemayehu; Menbere Alemu; Neal D E Alexander; Amir Bedri Kello; Berhanu Bero; Simon J Brooker; Brian K Chu; Michael Dejene; Paul M Emerson; Rebecca M Flueckiger; Solomon Gadisa; Katherine Gass; Teshome Gebre; Zelalem Habtamu; Erik Harvey; Dominic Haslam; Jonathan D King; Richard Le Mesurier; Susan Lewallen; Thomas M Lietman; Chad MacArthur; Silvio P Mariotti; Anna Massey; Els Mathieu; Addis Mekasha; Tom Millar; Caleb Mpyet; Beatriz E Muñoz; Jeremiah Ngondi; Stephanie Ogden; Joseph Pearce; Virginia Sarah; Alemayehu Sisay; Jennifer L Smith; Hugh R Taylor; Jo Thomson; Sheila K West; Rebecca Willis; Simon Bush; Danny Haddad; Allen Foster Journal: Ophthalmic Epidemiol Date: 2015 Impact factor: 1.648
Authors: François Missamou; Hemilembolo Marlhand; Angelie S Patrick Dzabatou-Babeaux; Samuel Sendzi; Jérôme Bernasconi; Susan D'Souza; Ana Bakhtiari; Tom Millar; Rebecca Willis; Karim Bengraïne; Serge Resnikoff; Anthony W Solomon Journal: Ophthalmic Epidemiol Date: 2018-12 Impact factor: 1.648
Authors: Colin K Macleod; Travis C Porco; Michael Dejene; Oumer Shafi; Biruck Kebede; Nebiyu Negussu; Berhanu Bero; Sadik Taju; Yilikal Adamu; Kassahun Negash; Tesfaye Haileselassie; John Riang; Ahmed Badei; Ana Bakhtiari; Rebecca Willis; Robin L Bailey; Anthony W Solomon Journal: Ophthalmic Epidemiol Date: 2018-12-28 Impact factor: 1.648